Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Christopher T Ritchlin

Showing results (181-190 of 201) with videos related to

Pageof 21
Sort By:
Arthritis Research & Therapy|December 20, 2011
Decreased influenza-specific B cell responses in rheumatoid arthritis patients treated with anti-tumor necrosis factorJames J Kobie, Bo Zheng, Peter Bryk, et al.
The Journal of Rheumatology|February 16, 2021
Proceedings of the 2020 GRAPPA Collaborative Research Network (CRN) MeetingCarmel Stober, Deepak R Jadon, April W Armstrong, et al.
Proceedings of the National Academy of Sciences of the United States of America|November 23, 2016
MIF allele-dependent regulation of the MIF coreceptor CD44 and role in rheumatoid arthritisSeung-Ah Yoo, Lin Leng, Bum-Joon Kim, et al.
Arthritis & Rheumatology (Hoboken, N.J.)|April 11, 2019
Selective Sexual Dimorphisms in Musculoskeletal and Cardiopulmonary Pathologic Manifestations and Mortality Incidence in the Tumor Necrosis Factor-Transgenic Mouse Model of Rheumatoid ArthritisRichard D Bell, Emily K Wu, Christopher A Rudmann, et al.
The Journal of Rheumatology. Supplement|June 3, 2020
Proceedings of the 2019 GRAPPA Collaborative Research Network MeetingRobin Waxman, Carmel Stober, Deepak R Jadon, et al.
The Journal of Rheumatology. Supplement|June 2, 2021
Proceedings of the 2020 GRAPPA Collaborative Research Network (CRN) MeetingCarmel Stober, Deepak R Jadon, April W Armstrong, et al.
RMD Open|February 22, 2024
Bimekizumab treatment in patients with active psoriatic arthritis and prior inadequate response to tumour necrosis factor inhibitors: 52-week safety and efficacy from the phase III BE COMPLETE study and its open-label extension BE VITALLaura C Coates, Robert Landewé, Iain B McInnes, et al.
Lancet (London, England)|December 10, 2022
Bimekizumab in patients with active psoriatic arthritis and previous inadequate response or intolerance to tumour necrosis factor-α inhibitors: a randomised, double-blind, placebo-controlled, phase 3 trial (BE COMPLETE)Joseph F Merola, Robert Landewé, Iain B McInnes, et al.
The Journal of Rheumatology|April 2, 2022
Proceedings of the 2021 GRAPPA-Collaborative Research Network (CRN) MeetingCarmel Stober, Iain B McInnes, Soumya Raychaudhuri, et al.
RMD Open|February 11, 2021
Guselkumab, an inhibitor of the IL-23p19 subunit, provides sustained improvement in signs and symptoms of active psoriatic arthritis: 1 year results of a phase III randomised study of patients who were biologic-naïve or TNFα inhibitor-experiencedChristopher T Ritchlin, Philip S Helliwell, Wolf-Henning Boehncke, et al.
Pageof 21

Showing results (181-190 of 201) with videos related to

Sort By:
Pageof 21
Arthritis Research & Therapy|December 20, 2011
Decreased influenza-specific B cell responses in rheumatoid arthritis patients treated with anti-tumor necrosis factorJames J Kobie, Bo Zheng, Peter Bryk, et al.
The Journal of Rheumatology|February 16, 2021
Proceedings of the 2020 GRAPPA Collaborative Research Network (CRN) MeetingCarmel Stober, Deepak R Jadon, April W Armstrong, et al.
Proceedings of the National Academy of Sciences of the United States of America|November 23, 2016
MIF allele-dependent regulation of the MIF coreceptor CD44 and role in rheumatoid arthritisSeung-Ah Yoo, Lin Leng, Bum-Joon Kim, et al.
Arthritis & Rheumatology (Hoboken, N.J.)|April 11, 2019
Selective Sexual Dimorphisms in Musculoskeletal and Cardiopulmonary Pathologic Manifestations and Mortality Incidence in the Tumor Necrosis Factor-Transgenic Mouse Model of Rheumatoid ArthritisRichard D Bell, Emily K Wu, Christopher A Rudmann, et al.
The Journal of Rheumatology. Supplement|June 3, 2020
Proceedings of the 2019 GRAPPA Collaborative Research Network MeetingRobin Waxman, Carmel Stober, Deepak R Jadon, et al.
The Journal of Rheumatology. Supplement|June 2, 2021
Proceedings of the 2020 GRAPPA Collaborative Research Network (CRN) MeetingCarmel Stober, Deepak R Jadon, April W Armstrong, et al.
RMD Open|February 22, 2024
Bimekizumab treatment in patients with active psoriatic arthritis and prior inadequate response to tumour necrosis factor inhibitors: 52-week safety and efficacy from the phase III BE COMPLETE study and its open-label extension BE VITALLaura C Coates, Robert Landewé, Iain B McInnes, et al.
Lancet (London, England)|December 10, 2022
Bimekizumab in patients with active psoriatic arthritis and previous inadequate response or intolerance to tumour necrosis factor-α inhibitors: a randomised, double-blind, placebo-controlled, phase 3 trial (BE COMPLETE)Joseph F Merola, Robert Landewé, Iain B McInnes, et al.
The Journal of Rheumatology|April 2, 2022
Proceedings of the 2021 GRAPPA-Collaborative Research Network (CRN) MeetingCarmel Stober, Iain B McInnes, Soumya Raychaudhuri, et al.
RMD Open|February 11, 2021
Guselkumab, an inhibitor of the IL-23p19 subunit, provides sustained improvement in signs and symptoms of active psoriatic arthritis: 1 year results of a phase III randomised study of patients who were biologic-naïve or TNFα inhibitor-experiencedChristopher T Ritchlin, Philip S Helliwell, Wolf-Henning Boehncke, et al.
Pageof 21